Exelixis Inc. Stock
Exelixis Inc. Stock
We can see a decrease in the price for Exelixis Inc.. Compared to yesterday it has lost -€0.350 (-1.580%).
With 15 Buy predictions and not the single Sell prediction the community is currently very high on Exelixis Inc..
With a target price of 26 € there is a slightly positive potential of 18.24% for Exelixis Inc. compared to the current price of 21.99 €.
Pros and Cons of Exelixis Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Cons
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Exelixis Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Exelixis Inc. | -1.580% | 1.057% | 0.091% | 32.350% | 0.503% | 7.373% | 22.849% |
Ironwood Pharmaceuticals | 0.690% | - | - | - | - | - | - |
Sage Therapeutics Inc. | -1.020% | 7.851% | -25.000% | -69.792% | -34.750% | -79.867% | - |
Novocure Ltd | -2.010% | 1.864% | -20.671% | -80.817% | -19.615% | -93.244% | - |
Comments
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Royal Bank of Canada from $26.00 to $28.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Barclays PLC from $24.00 to $25.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its "outperform" rating re-affirmed by analysts at William Blair.
Show more
Ratings data for EXEL provided by MarketBeat
News
Exelixis (EXEL) Q1 2024 Earnings Call Transcript
2 Stocks Under $30 to Buy and Hold
What is a reasonable sum of money to start investing in stocks? $10,000? $1,000? $500? The truth is, thanks to online brokers who now offer trades at low or no fees and fractional shares, investors